JP6865762B2 - セジラニブの一定間欠投与を含む方法 - Google Patents

セジラニブの一定間欠投与を含む方法 Download PDF

Info

Publication number
JP6865762B2
JP6865762B2 JP2018542709A JP2018542709A JP6865762B2 JP 6865762 B2 JP6865762 B2 JP 6865762B2 JP 2018542709 A JP2018542709 A JP 2018542709A JP 2018542709 A JP2018542709 A JP 2018542709A JP 6865762 B2 JP6865762 B2 JP 6865762B2
Authority
JP
Japan
Prior art keywords
sedilanib
composition
cancer
days
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018542709A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504860A (ja
JP2019504860A5 (enExample
Inventor
バリー，サイモン
ケンドリュー，ジェーン
ホー，トニー
ウェッジ，スティーヴン・ロバート
アイビー，スーザン・パーシー
コーン，エリーゼ
リー，ジョン−ミン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Government of the United States of America
Original Assignee
AstraZeneca AB
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB, Government of the United States of America filed Critical AstraZeneca AB
Publication of JP2019504860A publication Critical patent/JP2019504860A/ja
Publication of JP2019504860A5 publication Critical patent/JP2019504860A5/ja
Priority to JP2021064539A priority Critical patent/JP7271594B2/ja
Application granted granted Critical
Publication of JP6865762B2 publication Critical patent/JP6865762B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018542709A 2016-02-15 2017-02-14 セジラニブの一定間欠投与を含む方法 Active JP6865762B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021064539A JP7271594B2 (ja) 2016-02-15 2021-04-06 セジラニブの一定間欠投与を含む方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15
US62/295,421 2016-02-15
PCT/US2017/017804 WO2017142871A1 (en) 2016-02-15 2017-02-14 Methods comprising fixed intermittent dosing of cediranib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021064539A Division JP7271594B2 (ja) 2016-02-15 2021-04-06 セジラニブの一定間欠投与を含む方法

Publications (3)

Publication Number Publication Date
JP2019504860A JP2019504860A (ja) 2019-02-21
JP2019504860A5 JP2019504860A5 (enExample) 2020-03-26
JP6865762B2 true JP6865762B2 (ja) 2021-04-28

Family

ID=59625551

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018542709A Active JP6865762B2 (ja) 2016-02-15 2017-02-14 セジラニブの一定間欠投与を含む方法
JP2021064539A Active JP7271594B2 (ja) 2016-02-15 2021-04-06 セジラニブの一定間欠投与を含む方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021064539A Active JP7271594B2 (ja) 2016-02-15 2021-04-06 セジラニブの一定間欠投与を含む方法

Country Status (16)

Country Link
US (1) US20210322415A1 (enExample)
EP (2) EP4071174A1 (enExample)
JP (2) JP6865762B2 (enExample)
KR (1) KR102830910B1 (enExample)
CN (1) CN109073650A (enExample)
AU (1) AU2017221268B2 (enExample)
CA (1) CA3014674C (enExample)
DK (1) DK3417294T3 (enExample)
ES (1) ES2906813T3 (enExample)
HU (1) HUE058114T2 (enExample)
MA (1) MA44251A (enExample)
MX (2) MX2018009867A (enExample)
PL (1) PL3417294T3 (enExample)
RU (1) RU2740849C2 (enExample)
TW (1) TWI827530B (enExample)
WO (1) WO2017142871A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
MA50618A (fr) * 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2008514576A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
CA2715181A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
WO2010091140A1 (en) * 2009-02-04 2010-08-12 Bipar Sciences, Inc. Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
HK1201828A1 (en) * 2011-11-08 2015-09-11 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
JP6184423B2 (ja) * 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
MX389663B (es) * 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.

Also Published As

Publication number Publication date
TWI827530B (zh) 2024-01-01
US20210322415A1 (en) 2021-10-21
EP3417294A4 (en) 2019-08-14
CN109073650A (zh) 2018-12-21
TW201906610A (zh) 2019-02-16
CA3014674C (en) 2024-06-18
RU2018131377A3 (enExample) 2020-06-02
JP7271594B2 (ja) 2023-05-11
KR20180125456A (ko) 2018-11-23
ES2906813T3 (es) 2022-04-20
MX2018009867A (es) 2019-05-27
RU2740849C2 (ru) 2021-01-21
JP2019504860A (ja) 2019-02-21
KR102830910B1 (ko) 2025-07-04
MA44251A (fr) 2018-12-26
MX2023007826A (es) 2023-07-07
JP2021105039A (ja) 2021-07-26
DK3417294T3 (da) 2022-02-21
AU2017221268B2 (en) 2024-02-15
RU2018131377A (ru) 2020-03-17
WO2017142871A8 (en) 2018-06-14
WO2017142871A1 (en) 2017-08-24
EP3417294B8 (en) 2022-05-04
CA3014674A1 (en) 2017-08-24
PL3417294T3 (pl) 2022-05-09
EP3417294A1 (en) 2018-12-26
EP3417294B1 (en) 2021-12-01
HUE058114T2 (hu) 2022-07-28
AU2017221268A1 (en) 2018-08-30
EP4071174A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
JP7271594B2 (ja) セジラニブの一定間欠投与を含む方法
Geng et al. Molecular targeted drugs and treatment of colorectal cancer: recent progress and future perspectives
JP2010503717A (ja) Ｅｇｆｒ変異を有する腫瘍を治療するための方法
EP3313433A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
TW201839399A (zh) 癌症治療
EP3721906A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20210015787A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
EP4159238A1 (en) Combined pharmaceutical composition of c-met kinase inhibitor and anti-pd-l1 antibody
JP2008501006A (ja) Ｓｒｃキナーゼ阻害剤ＡＺＤ０５３０、および、抗エストロゲン剤またはＥＧＦＲ−ＴＫ−阻害剤を含む組み合わせ製品
JP2023550028A (ja) 固形腫瘍を治療するためのｋｒａｓｇ１２ｃ阻害剤及びｖｅｇｆ阻害剤を含む方法及び組成物
JP2022511929A (ja) がん
Sun et al. Systemic therapy for mutation-driven NSCLC
KR20250123210A (ko) Her2 억제제 고체 분산체의 투여 스케줄
TW202320790A (zh) 治療癌症之方法
HK40000757B (en) Methods comprising fixed intermittent dosing of cediranib
Crook et al. UTAH MEDICAID PT REPORT MAY 2024
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
CN118043049A (zh) 用于治疗包含kras g12c突变的癌症的索托拉西布和egfr抗体
TW202442232A (zh) 用於治療局部晚期不可切除或轉移性結直腸癌的藥物及其用途
TW202535407A (zh) 治療癌症的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210319

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210406

R150 Certificate of patent or registration of utility model

Ref document number: 6865762

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250